Ventfort
Ventfort is a complex peptide bioregulator preparation derived from vascular tissue, developed to support endothelial function and blood vessel integrity. Research focuses on its potential to improve vascular health in aging, atherosclerosis models, and endothelial dysfunction through tissue-specific gene regulation.
Ventfort is a complex peptide preparation classified as a cytomedine — a tissue-specific bioregulator developed at the St. Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson's research program.
Overview
Ventfort was developed within the framework of Khavinson's bioregulatory peptide theory, which holds that tissue-derived peptide extracts can normalize gene expression in aging or damaged cells, restoring more youthful functional states (Khavinson, 2005). The preparation is produced through standardized extraction of low-molecular-weight peptides from animal vascular tissue, following the same methodology used for other established cytomedines.
The vascular system undergoes significant age-related changes, including endothelial dysfunction, increased arterial stiffness, reduced nitric oxide bioavailability, and progressive atherosclerotic remodeling. These changes are driven by alterations in gene expression within endothelial cells and vascular smooth muscle cells. Ventfort is designed to address these changes through tissue-specific peptide signaling.
Mechanism of Action
Ventfort's proposed mechanism aligns with the established bioregulatory peptide model. The peptide complex is thought to contain sequences that interact with DNA regulatory elements specific to vascular tissue, modulating gene expression in endothelial cells and vascular smooth muscle cells. Proposed effects include:
- Endothelial function restoration through upregulation of endothelial nitric oxide synthase (eNOS) and improved nitric oxide production, which is critical for vasodilation and vascular homeostasis
- Anti-atherogenic effects by modulating the expression of adhesion molecules (VCAM-1, ICAM-1) on endothelial surfaces, reducing monocyte recruitment and inflammatory cell infiltration into the vessel wall
- Vascular smooth muscle regulation through normalization of proliferative signaling in smooth muscle cells, reducing the pathological intimal thickening characteristic of atherosclerosis
- Antioxidant defense enhancement by supporting endogenous antioxidant enzyme expression in vascular tissue, countering the oxidative stress that drives endothelial damage
Research by Khavinson's group has demonstrated that vascular peptide bioregulators can influence endothelial cell behavior in culture, with effects more pronounced in cells from older donors — consistent with the pattern observed across the cytomedine class (Khavinson et al., 2012).
Research
Endothelial Function and Vascular Aging
Endothelial dysfunction is considered a central mechanism of vascular aging and a precursor to atherosclerosis, hypertension, and other cardiovascular diseases. The endothelium regulates vascular tone, permeability, inflammation, and thrombosis through a complex network of signaling molecules. With aging, endothelial cells progressively lose their ability to produce nitric oxide and maintain barrier function.
Khavinson and colleagues have studied the effects of vascular-targeted peptide bioregulators on endothelial cells, demonstrating that these preparations can stimulate cell differentiation and restore functional markers in aging cell cultures. The tissue-specific nature of these effects has been established across multiple cytomedines (Khavinson et al., 2012), supporting the concept that vascular peptide extracts preferentially act on blood vessel cells.
Atherosclerosis and Vascular Remodeling
Atherosclerosis involves a cascade of events beginning with endothelial injury and progressing through lipid accumulation, inflammatory cell recruitment, smooth muscle cell migration, and plaque formation. Bioregulatory peptides targeting vascular tissue are hypothesized to intervene at multiple points in this cascade by normalizing gene expression in both endothelial and smooth muscle cells.
The broader bioregulatory peptide literature demonstrates that short peptides can modulate inflammatory pathways including NF-kB signaling (Ashapkin et al., 2020), which plays a central role in atherogenesis. Ventfort's vascular-specific peptide mixture is expected to exert these anti-inflammatory effects preferentially in blood vessel tissue.
Cardiovascular Risk and Geroprotection
Khavinson's long-term geroprotective studies have included vascular bioregulators as part of multi-component anti-aging protocols. The theoretical basis for this approach is that normalizing vascular gene expression can reduce cardiovascular risk factors associated with aging, including arterial stiffness, hypertension, and impaired microvascular function. Khavinson's landmark review on peptides and aging outlined the rationale for tissue-specific bioregulation across organ systems, including the vasculature (Khavinson, 2005).
Safety Profile
Ventfort has a safety profile consistent with other cytomedine preparations in the Khavinson series. As a complex of naturally occurring low-molecular-weight peptides, it is rapidly metabolized through normal proteolytic pathways and is not expected to accumulate in tissues. These preparations have been used in Russian clinical practice for extended periods without reports of significant adverse effects.
Formal toxicology studies and controlled clinical trials published in international peer-reviewed journals remain limited. Individuals with active vascular malformations, proliferative retinopathy, or conditions where angiogenesis could be harmful should exercise caution, as the effects of vascular bioregulators on new blood vessel formation are not fully characterized.
Pharmacokinetic Profile
- Half-life
- Not established
Quick Start
- Route
- Oral
Molecular Structure
- Formula
- Not applicable (polypeptide complex)
- CAS
- Not available
Research Protocols
oral
Administered via oral.
Quality Indicators
What to look for
- Naturally occurring compound
- Multiple peer-reviewed studies available
Frequently Asked Questions
References (4)
- [2][Khavinson VK et al. (2012). Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med (2012)
- [1][Khavinson VK (2005). Peptides and ageing. Neuro Endocrinol Lett (2005)
- [3][Ashapkin V et al. (2020). Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep (2020)
- [4][Khavinson VK et al. (2021). Peptide Regulation of Gene Expression: A Systematic Review. Molecules (2021)
Urotensin II
Urotensin II (UII) is a cyclic peptide identified as the most potent vasoconstrictor discovered to date. Acting through the UT receptor (GPR14), it has complex cardiovascular effects including vasoconstriction, positive inotropy, and promotion of cardiac remodeling, with pathological elevation in heart failure, pulmonary hypertension, and atherosclerosis.
Vilon
Vilon (Lys-Glu, KE dipeptide) is a synthetic dipeptide bioregulator developed by Khavinson's group at the Saint Petersburg Institute of Bioregulation and Gerontology. Designed to mimic thymulin (FTS) activity, Vilon stimulates T-lymphocyte differentiation, modulates CD4/CD8 ratios, influences IL-2 and IFN-gamma production, and regulates gene expression through direct peptide-DNA binding.